Biotech Values

[ghmm]

BioMS:

Got around to listening to the call. Add me to the skeptical group. They defined meeting a secondary end point as p < .15 though they did say at least one end point was < .05. They will publish the data at some scientific meeting in the future.

If you believe there is a difference in disease states perhaps it would be a fruitful investment but though I am not an MS expert by any means it doesn't make sense to me. Maybe if they publish and the results aren't too far off one could argue the size of the trial and the drug has some efficacy just not substantial but with several mid/late stage MS drugs in development I am not sure I would invest here.